Scarica l'app Stockscreener
8.505
0.06%
0.005
Precedente Chiudi:
$8.50
Aprire:
$8.5
Volume 24 ore:
1.58M
Relative Volume:
0.43
Capitalizzazione di mercato:
$797.80M
Reddito:
$324.00K
Utile/perdita netta:
$-82.10M
Rapporto P/E:
-9.1452
EPS:
-0.93
Flusso di cassa netto:
$-69.18M
1 W Prestazione:
+0.06%
1M Prestazione:
+62.00%
6M Prestazione:
+814.52%
1 anno Prestazione:
+702.36%
Intervallo 1D:
$8.50
$8.51
Intervallo di 1 settimana:
$8.50
$8.53
Portata 52W:
$0.75
$8.53
Chimerix Inc Stock (CMRX) Company Profile
Nome
Chimerix Inc
Settore
Industria
Telefono
919.806.1074
Indirizzo
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Confronta CMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMRX
Chimerix Inc
|
8.505 | 797.80M | 324.00K | -82.10M | -69.18M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.74 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.84 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.74 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.65 | 33.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.51 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Chimerix Inc Stock (CMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-05-23 | Iniziato | Robert W. Baird | Outperform |
| 2022-09-07 | Iniziato | CapitalOne | Overweight |
| 2021-04-29 | Iniziato | Maxim Group | Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-31 | Iniziato | Jefferies | Buy |
| 2021-03-31 | Iniziato | Wedbush | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-02-02 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-09 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2016-02-23 | Reiterato | FBR Capital | Mkt Perform |
| 2016-02-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2016-02-22 | Downgrade | Citigroup | Buy → Neutral |
| 2015-12-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-28 | Downgrade | FBR Capital | Outperform → Mkt Perform |
| 2015-12-28 | Reiterato | Piper Jaffray | Overweight |
| 2015-12-17 | Iniziato | UBS | Buy |
| 2015-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-09-03 | Iniziato | Citigroup | Buy |
| 2015-08-18 | Iniziato | FBR Capital | Outperform |
| 2015-08-06 | Reiterato | Brean Capital | Buy |
| 2015-05-11 | Reiterato | Brean Capital | Buy |
| 2015-03-04 | Iniziato | Barclays | Overweight |
| 2015-02-12 | Reiterato | Stifel | Buy |
| 2014-12-31 | Reiterato | Brean Capital | Buy |
| 2014-07-08 | Ripresa | Brean Capital | Buy |
Mostra tutto
Chimerix Inc Borsa (CMRX) Ultime notizie
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 - Yahoo Finance
Chimerix stock soars to 52-week high, hits $8.53 By Investing.com - Investing.com South Africa
Chimerix stock soars to 52-week high, hits $8.53 - Investing.com
11 Best Performing Stocks So Far In 2025 - Insider Monkey
Chimerix earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Chimerix Inc Reports Q4 2024 EPS of -$0.25, Beating Estimates; R - GuruFocus.com
The buildup to Chimerix's $935M exit to Jazz, with more than half a dozen parties intrigued - Endpoints News
Chimerix: Q4 Earnings Snapshot - mySA
Chimerix Inc. (CMRX) reports earnings - Quartz
CHIMERIX INC SEC 10-K Report - TradingView
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - The Manila Times
Chimerix: Q4 Earnings Snapshot -March 21, 2025 at 06:07 am EDT - MarketScreener
Chimerix Reports Earnings as $935M Jazz Buyout and FDA Drug Review Advance - StockTitan
Investment Analysts’ Recent Ratings Updates for Chimerix (CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $8.47 By Investing.com - Investing.com Australia
Chimerix stock soars to 52-week high, hits $8.47 - Investing.com India
Ireland: Jazz adds to oncology pipeline with Chimerix - Investors in Healthcare
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.
Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Finansavisen
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - Financial Content
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire
Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
Chimerix Expands Team with Strategic New Hire, Offers 70K Share Options Package - StockTitan
Chimerix, Inc. to Host Earnings Call - ACCESS Newswire
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - GlobeNewswire
HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Top Medical Stocks To Add to Your Watchlist – March 5th - Defense World
Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX) - Defense World
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Best Pharmaceutical Stocks To Watch Today – March 5th - Defense World
Wedbush Reaffirms “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - TradingView
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Chimerix downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga India
Jazz Pharmaceuticals to acquire Chimerix for $935m - World Pharmaceutical Frontiers
Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN
Jazz Pharmaceuticals bids for Chimerix in $935m deal - MSN
CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz - MSN
Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio - Genetic Engineering & Biotechnology News
Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada
Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld MedTech
Chimerix Stock Hold Rating: Limited Upside Due to Acquisition Offer Price Alignment - TipRanks
Chimerix Inc Azioni (CMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):